Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase in patients with hypercholesterolemia: Results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial

Journal of the American College of Cardiology

Volumn 62, Issue 13, 2013, Pages 1154-1162

  Ballantyne, Christie M ^a,b   Davidson, Michael H ^c   MacDougall, Diane E ^d   Bays, Harold E ^e   Dicarlo, Lorenzo A ^d   Rosenberg, Noah L ^d   Margulies, Janice ^d   Newton, Roger S ^d  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d Esperion Therapeutics Inc   (United States)

^e LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER   (United States)

Author keywords

cardiovascular disease; low density lipoprotein cholesterol; prevention; risk factors

Indexed keywords

8 HYDROXY 2,2,14,14 TETRAMETHYLPENTADECANEDIOIC ACID; ADENOSINE TRIPHOSPHATE CITRATE LYASE; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; C REACTIVE PROTEIN; CHOLESTEROL; ETC 1002; FATTY ACID; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; HYPOCHOLESTEROLEMIC AGENT; INSULIN; LOW DENSITY LIPOPROTEIN RECEPTOR; PLACEBO; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ABDOMINAL DISCOMFORT; ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; ANEMIA; ARTHRALGIA; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY MASS; CARDIOMETABOLIC RISK; CONSTIPATION; CONTROLLED STUDY; COUGHING; CREATINE KINASE BLOOD LEVEL; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; DYSPEPSIA; DYSPNEA; ENERGY; ERYTHROCYTE COUNT; FATIGUE; FEMALE; FLATULENCE; GASTROESOPHAGEAL REFLUX; GOUT; HEADACHE; HEMATOCRIT; HUMAN; HUNGER; HYPERCHOLESTEROLEMIA; HYPERESTHESIA; INSULIN SENSITIVITY; INTERNATIONAL NORMALIZED RATIO; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE RIGIDITY; MUSCLE SPASM; MUSCLE TIGHTNESS; MYALGIA; NAUSEA; NIGHTMARE; PARESTHESIA; PERIODONTAL DISEASE; PERIPHERAL EDEMA; POLLAKISURIA; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; RISK FACTOR; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; SUPERNATANT; SYSTOLIC BLOOD PRESSURE; URINARY TRACT INFECTION; VISUAL IMPAIRMENT; VOMITING; WEIGHT GAIN;

ACL; ADENOSINE MONOPHOSPHATE-ACTIVATED PROTEIN KINASE; ADENOSINE TRIPHOSPHATE-CITRATE LYASE; AMPK; APO; APOLIPOPROTEIN; CARDIOVASCULAR DISEASE; HDL-C; HIGH-DENSITY LIPOPROTEIN CHOLESTEROL; HIGH-SENSITIVITY C-REACTIVE PROTEIN; HSCRP; LDL-C; LOW-DENSITY LIPOPROTEIN CHOLESTEROL; MITT; MODIFIED INTENT-TO-TREAT; PREVENTION; RISK FACTORS; ULN; UPPER LIMIT OF NORMAL;

AGED; AMP-ACTIVATED PROTEIN KINASES; ATP CITRATE (PRO-S)-LYASE; DICARBOXYLIC ACIDS; DOUBLE-BLIND METHOD; FATTY ACIDS; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; HYPOLIPIDEMIC AGENTS; MALE; MIDDLE AGED; RISK FACTORS;

EID: 84884366154     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2013.05.050     Document Type: Article

References (29)

1. D.D. Waters What the statin trials have taught us Am J Cardiol 98 2006 129 134
2. S.M. Grundy, J.I. Cleeman, and C.N. Merz Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines Circulation 110 2004 227 239
3. S.S. Martin, K. Gosch, and K.R. Kulkarni Modifiable factors associated with failure to attain low-density lipoprotein cholesterol goal at 6 months after acute myocardial infarction Am Heart J 165 2013 26 33.e3
4. S.S. Virani, L.D. Woodard, and S.S. Chitwood Frequency and correlates of treatment intensification for elevated cholesterol levels in patients with cardiovascular disease Am Heart J 162 2011 725 732.e1
5. S.L. Pinkosky, S. Filippov, and R.A. Srivastava AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism J Lipid Res 54 2013 134 151
6. Srivastava RA, Hurley TR, Brant AF, et al. A novel small molecule, ETC-1002, lowers proatherogenic lipoproteins, reduces adiposity, and improves hepatic steatosis in a hyperlipidemic hamster model (abstr 25085). Presented at: American Heart Association Scientific Sessions 2011; November 12-16, 2011; Orlando, FL.
7. Hanselman JC, Bradshaw CD, Brant AF, et al. ETC-1002 reduces circulating and hepatic triglyceride content and improves glycemic control in KKAy mice (abstr 554). Presented at: ATVB Scientific Sessions 2011; April 28-30, 2011; Chicago, IL.
8. C.T. Cramer, B. Goetz, and K.L. Hopson Effects of a novel dual lipid synthesis inhibitor and its potential utility in treating dyslipidemia and metabolic syndrome J Lipid Res 45 2004 1289 1301
9. G.L. Myers, G.R. Cooper, C.L. Winn, and S.J. Smith The Centers for Disease Control-National Heart, Lung and Blood Institute Lipid Standardization Program. An approach to accurate and precise lipid measurements Clin Lab Med 9 1989 105 135
10. A. Rabinovitch The College of American Pathologists laboratory accreditation program Accred Qual Assur 7 2002 473 476
11. G.R. Warnick, and J.J. Albers A comprehensive evaluation of the heparin-manganese precipitation procedure for estimating high density lipoprotein cholesterol J Lipid Res 19 1978 65 76
12. W.T. Friedewald, R.I. Levy, and D.S. Frederickson Estimation of concentration of low density lipoprotein cholesterol in plasma, without using preparative ultracentrifuge Clin Chem 18 1972 499 522
13. US Department of Health and Human Services Lipid Research Clinics manual of laboratory operations: lipid and lipoprotein analysis (revised) 1982 Government Printing Office Washington, DC Publication no. (NIH) 75-67815
14. E.J. Jeyarajah, W.C. Cromwell, and J.D. Otvos Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy Clin Lab Med 26 2006 847 870
15. V.L. Roger, A.S. Go, and D.M. Lloyd-Jones Heart and stroke statistics - 2012 update: a report from the American Heart Association Circulation 125 2012 e2 e20
16. P.A. Heidenreich, J.G. Trogdon, and O.A. Khavjou Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association Circulation 123 2011 933 944
17. A. Egan, and E. Colman Weighting the benefits of high-dose simvastatin against the risk of myopathy N Engl J Med 365 2011 285 287
18. J.D. Cohen, E.A. Brinton, M.K. Ito, and T.A. Jacobson Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users J Clin Lipidol 6 2012 208 215
19. N. Sattar, D. Preiss, and H.M. Murray Statins and risk of incident diabetes: a collaborative meta-analysis of randomized statin trials Lancet 375 2010 735 742
20. D. Preiss, S.R.K. Seshasai, and P. Welsh Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy JAMA 305 2011 2556 2564
21. US Food and Drug Administration. FDA Drug Safety Communication: Important safety label changes to cholesterol lowering statin drugs [press release]. Available at: http://www.fda.gov/Drugs/Drug Safety/ucm293101.htm. Accessed February 1, 2013.
22. R.H. Knopp, C.A. Dujovne, and A. LeBeaut Evaluation of the efficacy, safety and tolerability of ezetimibe in primary hypercholesterolemia: a pooled analysis from two controlled phase III clinical studies Int J Clin Pract 57 2003 363 368
23. W. Insull, P. Toth, and W. Mullican Effectiveness of colesevelam hydrochloride in decreasing LDL cholesterol in patients with primary hypercholesterolemia: a 24-week randomized controlled trial Mayo Clin Proc 76 2001 971 982
24. A.C. Goldberg Clinical trial experience with extended-release niacin (Niaspan): dose-escalation study Am J Cardiol 82 1998 35U 38U
25. R.H. Knopp, W.V. Brown, and C.A. Dujovne Effects of fenofibrate on plasma lipoproteins in hypercholesterolemia and combined hyperlipidemia Am J Med 83 1987 50 59
26. M.K. Hellerstein De novo lipogenesis in humans: metabolic and regulatory aspects Eur J Clin Nutr 53 1999 S53 S65
27. J.F. Ascasso, S. Pardo, and J.T. Real Diagnosing insulin resistance by simple quantitative methods in subjects with normal glucose metabolism Diabetes Care 26 2003 3320 3325
28. P.M. Ridker, E. Danielson, and F.A. Fonseca Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein N Engl J Med 359 2008 2195 2207
29. J. Dierkes, C. Luley, and S. Westphal Effect of lipid-lowering and anti-hypertensive drugs on plasma homocysteine levels Vascular Health and Risk Management 3 2001 99 108